Bio-Techne (TECH) skyrocketed on June 25 after German science and technology company Merck KGaA (MKKGY) announced a definitive agreement to acquire it for $73 per share.
The all-cash transaction values TECH at an enterprise value of about $11.3 billion, representing a rather significant 24% premium over its previous closing price.